Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most clinical label-linked claims (indication, mechanism reducing evaporation, dosing conceptually related to DED/blurred vision) are generally consistent, but several administrative/dispensing/prescriber-setting claims and at least one safety frequency claim are not supported by the provided label text.
Category Scores
Accurate Statements
Miebo is a prescription eye drop used to treat the signs and symptoms of dry eye disease.
Section 1 (INDICATIONS AND USAGE): indicated for treatment of the signs and symptoms of dry eye disease (DED).
Miebo works by preventing tear evaporation caused by meibomian gland dysfunction (MGD).
Section 12.1 (Mechanism of Action): forms a monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation. (Label also notes exact mechanism for MIEBO in DED is not known.)
MGD is a common cause of dry eye disease.
Label provided states trials enrolled patients with signs of meibomian gland dysfunction (Section 14), but the provided label text does not explicitly say MGD is a 'common cause.' Therefore this is not confirmed by label wording.
The most common side effect of Miebo is temporary blurred vision.
Section 6.1 (Adverse Reactions): most common ocular adverse reaction was blurred vision.
Miebo was approved by the U.S. Food and Drug Administration (FDA) in May 2023.
Unsupported Statements
Miebo is available at retail pharmacies such as CVS and Walgreens.
Provided label text does not mention retail distribution channels or specific pharmacies.
Miebo does not require a specialty pharmacy for dispensing.
Provided label text does not discuss dispensing channel requirements (e.g., specialty pharmacy vs retail).
Miebo can be prescribed by any licensed healthcare provider.
Provided label text does not specify prescriber eligibility categories.
Once prescribed, Miebo can be filled at a local retail pharmacy.
Provided label text does not address where prescriptions can be filled (retail vs specialty).
The most common side effect of Miebo is temporary blurred vision.
Label supports blurred vision as the most common ocular adverse reaction, but the provided label text does not state it is 'temporary.'
MGD is a common cause of dry eye disease.
Provided label text does not explicitly state MGD is a 'common cause' of DED.
Miebo works by preventing tear evaporation caused by meibomian gland dysfunction (MGD).
Label supports reduction of evaporation, and trials involve meibomian gland dysfunction, but the provided label text does not explicitly link MIEBO's effect to evaporation 'caused by MGD.' Also label states exact mechanism for MIEBO in DED is not known.
Miebo was approved by the U.S. Food and Drug Administration (FDA) in May 2023.
Provided label text does not provide FDA approval date information.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Contact lens administration restriction (remove lenses prior to and for at least 30 minutes after administration).
Importance:
Moderate
Recommended dosage (one drop four times daily into affected eye(s)).
Importance:
Moderate
Contraindication for hypersensitivity to perfluorohexyloctane.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Clinical safety content is partially aligned (blurred vision as most common ocular adverse reaction), but missing label-critical administration guidance (contact lens removal window) and unsupported claims about dispensing/prescriber setting could lead to improper use or misleading distribution expectations. No direct label contraindication conflicts were identified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims about dispensing/prescriber/approval date and parts of clinical mechanism/safety descriptions are not supported by the provided label text.
Suggested Improvement
Limit claims to label-supported information provided: indication (DED signs/symptoms), mechanism reducing tear evaporation (without asserting MGD causality linkage), blurred vision as most common ocular adverse reaction (without claiming 'temporary'), and remove unsupported statements about pharmacy networks, prescriber eligibility, and approval date. Include label-required administration/contact lens timing and dosing if making usage claims.